A screenshot of the YouTube video featuring Adrian Hernandez and Clive Meanwell.
Scroll to the bottom of the page to view a discussion between Adrian Hernandez, MD, MHS, DCRI's executive director, and Clive Meanwell, MD, on the landscape of anti-obesity medications.

Anti-Obesity Pharmacotherapy

Oct. 2024 DCRI Think Tank Spotlight

Share

Obesity impacts the lives of ~150 million individuals in the U.S. Not only does it affect every facet of the lives of these individuals, but it also results in a societal cost of ~425 billion USD annually. With recent advances in anti-obesity therapy, the healthcare system finds itself in a situation where a chronic condition that affects a large proportion of the population is now eligible for highly effective but currently expensive therapies.

The October 2024 DCRI Think Tanks meeting on “Anti-Obesity Pharmacotherapy: An Urgent Need for Guidance, Access, and Equity” aimed to tackle this issue head-on by bringing together partners from academia, government, industry, and patient/community organizations to discuss:

  • Redefining obesity: Moving beyond simplistic BMI-based definitions to capture the complexity of this chronic neuroendocrine disease.
  • Evaluating anti-obesity medications (AOMs) value and costs: Accounting for long-term clinical outcomes, not just upfront medication prices.
  • Ensuring equitable access: Addressing disparities in obesity prevalence and treatment, starting with representative clinical trials.
Read the Meeting Summary

Watch the videos of our strategic collaborators and read the meeting brief to learn more about the landscape, challenges, and next steps discussed by our partners at this meeting.

Adrian Hernandez, MD, MHS, DCRI's executive director, and Clive Meanwell, MD, chairman and managing partners of Population Health Partners, sit down to discuss the landscape of anti-obesity medications and the potential impact on populations.
Yale University School of Medicine cardiologist Harlan Krumholz, MD, and Joe Nadglowski, president and CEO of the Obesity Action Coalition, discuss the patient experience, how providers can better connect with those with obesity, and where anti-obesity medications fit in.

Share